๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Annovis Bio, Inc. (ANVS)
NYSE: ANVS ยท Real-Time Price ยท USD
0.7113
-0.0371 (-4.96%)
At close: Nov 20, 2026, 4:00 PM EST
0.7300
+0.0187 (2.63%)
After-hours: Nov 20, 2026, 7:53 PM EST

Annovis Bio Earnings Call Transcripts

Fiscal Year 2026

  • Investor update

    Pivotal phase III Alzheimer's trial is fully enrolled, with top-line data expected in March and NDA filing to follow. Additional funding is required to continue operations, with management and insiders planning to participate in the raise. Disease-modifying data in 2028 could unlock significant market opportunities.

Fiscal Year 2025

  • A new orally available Alzheimer's drug targets four toxic proteins, showing both symptomatic and disease-modifying effects in animal and human studies. It demonstrated significant cognitive improvement and broad efficacy across patient subgroups, with an 18-month pivotal trial ongoing.

  • Status Update

    The pivotal phase III Alzheimer's trial is progressing, with full enrollment expected by year-end and key data readouts planned for fall and 2027. Early results show strong efficacy and safety, while Parkinson's studies await funding. Regulatory and investor engagement remains active.